S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
Log in

NASDAQ:ENTAEnanta Pharmaceuticals Stock Price, Forecast & News

$51.67
+1.65 (+3.30 %)
(As of 07/15/2020 04:00 PM ET)
Add
Compare
Today's Range
$49.81
Now: $51.67
$51.69
50-Day Range
$48.24
MA: $50.41
$55.30
52-Week Range
$38.40
Now: $51.67
$84.73
Volume219,200 shs
Average Volume202,941 shs
Market Capitalization$1.03 billion
P/E Ratio46.13
Dividend YieldN/A
Beta0.54
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Read More
Enanta Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.28 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ENTA
CUSIPN/A
Phone617-607-0800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$205.20 million
Cash Flow$2.30 per share
Book Value$23.50 per share

Profitability

Net Income$46.38 million

Miscellaneous

Employees113
Market Cap$1.03 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive ENTA News and Ratings via Email

Sign-up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.

Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions

How has Enanta Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Enanta Pharmaceuticals' stock was trading at $52.92 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ENTA stock has decreased by 2.4% and is now trading at $51.67. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Enanta Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Enanta Pharmaceuticals.

When is Enanta Pharmaceuticals' next earnings date?

Enanta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Enanta Pharmaceuticals.

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) released its earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.30) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.73) by $0.43. The biotechnology company had revenue of $27.60 million for the quarter, compared to analysts' expectations of $29.16 million. Enanta Pharmaceuticals had a net margin of 13.46% and a return on equity of 5.04%. Enanta Pharmaceuticals's quarterly revenue was down 30.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.20 earnings per share. View Enanta Pharmaceuticals' earnings history.

What price target have analysts set for ENTA?

6 equities research analysts have issued 1 year price targets for Enanta Pharmaceuticals' stock. Their forecasts range from $49.00 to $130.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $71.60 in the next twelve months. This suggests a possible upside of 38.6% from the stock's current price. View analysts' price targets for Enanta Pharmaceuticals.

Has Enanta Pharmaceuticals been receiving favorable news coverage?

News articles about ENTA stock have trended extremely negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Enanta Pharmaceuticals earned a daily sentiment score of -4.3 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an impact on the company's share price in the near term. View the latest news about Enanta Pharmaceuticals.

Who are some of Enanta Pharmaceuticals' key competitors?

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), Gilead Sciences (GILD), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), GW Pharmaceuticals PLC- (GWPH) and Netflix (NFLX).

Who are Enanta Pharmaceuticals' key executives?

Enanta Pharmaceuticals' management team includes the following people:
  • Dr. Jay R. Luly, Pres, CEO & Director (Age 63)
  • Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 64)
  • Dr. Yat Sun Or, Sr. VP of R&D and Chief Scientific Officer (Age 67)
  • Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 65)
  • Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 53)

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Wedge Capital Management L L P NC (0.02%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View institutional ownership trends for Enanta Pharmaceuticals.

Which major investors are selling Enanta Pharmaceuticals stock?

ENTA stock was sold by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC. View insider buying and selling activity for Enanta Pharmaceuticals.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $51.67.

How big of a company is Enanta Pharmaceuticals?

Enanta Pharmaceuticals has a market capitalization of $1.03 billion and generates $205.20 million in revenue each year. The biotechnology company earns $46.38 million in net income (profit) each year or $2.21 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.

What is Enanta Pharmaceuticals' official website?

The official website for Enanta Pharmaceuticals is www.enanta.com.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.